top of page
The Professional Network for Healthcare Experts
GSK acquires Chimagen trispecific T-cell engager programme in deal worth up to $750m
GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.
nuaxia
Sep 162 min read
Roche signs $1.53bn global licensing deal for Simcere's B-cell antibody SIM0660
The agreement gives Roche exclusive global rights to develop, manufacture and commercialise Simcere Zaiming's investigational trispecific antibody SIM0660 outside Greater China.
nuaxia
Sep 22 min read
bottom of page